LYT-200
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
MDS Centers of Excellence
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Sort by
Center of Excellence
Cedars-Sinai Medical Center - UCLA School of Medicine
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
- Accepting patients
- Accepting patients
- Accepting patients
- Accepting patients
Center of Excellence
Massachusetts General Hospital
Boston, MA
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
- Accepting patients
Lifespan Rhode Island Hospital
Providence, RI
- Accepting patients
Virginia Commonwealth University Medical Center
Richmond, VA
- Accepting patients
507 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.